German commercial-stage diagnostic company Centogene N.V. has extended its partnership with Japanese pharma company Takeda Pharmaceuticals for one year to provide diagnostic testing for Lysosomal Storage Disorders (LSDs), including Fabry disease, Gaucher disease, and Hunter syndrome.
The partnership aims to enhance patient access to rapid and reliable diagnostics for LSDs by leveraging CENTOGENE's targeted diagnostic portfolio, network of over 30,000 active physicians, and the CENTOGENE Biodatabank, which currently contains data for approximately 700,000 patients representing over 120 highly diverse countries. The partnership will continue to play a vital role in the expansion of Takeda's enzyme replacement treatments and provide life-changing answers to underserved patient communities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.